Transforming The Management Of Critical Bleeding and Clotting

HemoSonics is bringing to market a next-generation point-of-care diagnostic platform, the Quantra Dx, that provides actionable information to guide the management of critical bleeding and clotting.

Our goal is to improve outcomes and reduce healthcare costs by enabling more targeted selection and dosing of blood products in critical settings. We seek to transform the way clinicians manage coagulation dysfunctions by providing comprehensive, timely and accurate information on coagulation status at the point of care, enabling clinicians to rapidly choose the right treatment, dramatically improving outcomes and lowering treatment costs.

Our Products

The Quantra Dx™ is a rapid, easy-to-use, point-of-care diagnostic platform that fully characterizes and guides the management of critical bleeding.
Learn more.

Our Technology

Our patented SEER sonorheometry technology quantifies coagulation by measuring the evolving stiffness of clotting blood.
Learn more.

Our Leadership

Our team has a proven track record of successfully developing and bringing to market innovative medical devices.
Learn more.

Blood cells

Studies show that use of comprehensive point-of-care coagulation testing in surgical settings leads to:

Improved clinical outcomes

  • Fewer transfusions
  • Fewer complications

Reduced cost of care

  • Reduced blood product utilization
  • Shorter inpatient stays

NEWSFEED

HemoSonics Expands Management Team

Seasoned Diagnostic Executives Bolster Leadership in Preparation for Regulatory Process and Commercialization Charlottesville, VA – May 2, 2015 – HemoSonics, a medical device company developing a point-of-care diagnostic platform to guide the management of critical... read more

HemoSonics Awarded $2M NIH Phase IIB Grant

Phase IIB Grant to Fund Commercialization Activities for the Quantra DxTM Platform Charlottesville, VA – March 10, 2015 – HemoSonics, a medical device company developing a point-of-care diagnostic platform to guide the management of critical bleeding, today announced... read more

PennsylvaniaBIO